Physician profile

Violeta Martel

Internal Medicine · Santee, CA

NPI 1104903178

$2,162.35

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$134.47

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $1,024.71 2019-2020
Sunovion Pharmaceuticals INC. $244.86 2019-2020
Bayer Healthcare Pharmaceuticals INC. $134.47 2023
Radius Health, INC. $121.84 2019
Portola Pharmaceuticals, LLC $119.48 2019
Pfizer INC. $117.74 2019
Novartis Pharmaceuticals Corporation $113.72 2019
Avanir Pharmaceuticals, INC. $106.72 2019
Medtronic Vascular, INC. $89.84 2019
Lilly USA, LLC $88.97 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Violeta Martel

$2,162.35

in general payments reported 2019-2025

Years
2019-2023
Top company
Janssen Pharmaceuticals, INC

https://glasscript.com/doctor/185833/violeta-martel

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.